GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dongkook Pharmaceutical Co 086450.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

23,350

-0.85%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩926.88bn

FY2016FY2025

Net income

₩66.02bn

FY2016FY2025

Free cash flow

₩22.76bn

FY2016FY2025

Shareholders' equity

₩663.74bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩926.88bn₩812.17bn₩730.99bn₩661.65bn₩594.19bn₩559.10bn₩482.28bn₩400.81bn₩354.77bn₩309.69bn
Gross profit₩501.60bn₩447.90bn₩410.78bn₩379.83bn₩350.26bn₩337.41bn₩290.83bn₩237.95bn₩209.36bn₩182.91bn
Research and development₩32.82bn₩30.33bn₩25.46bn₩23.10bn₩24.69bn₩18.86bn₩19.89bn₩15.96bn₩12.79bn₩10.41bn
Operating income₩96.55bn₩80.42bn₩66.87bn₩72.65bn₩63.22bn₩84.72bn₩68.57bn₩55.10bn₩50.06bn₩46.92bn
Net income₩66.02bn₩61.22bn₩47.18bn₩52.90bn₩50.35bn₩55.93bn₩56.31bn₩46.95bn₩39.60bn₩40.66bn
Diluted earnings per share1,487.211,392.341,073.081,203.401,145.561,272.521,281.335,201.054,504.29925.17

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩1.06trn₩953.16bn₩839.54bn₩768.33bn₩750.08bn₩663.17bn₩544.38bn₩480.24bn₩373.31bn₩325.10bn
Cash and short-term investments—₩88.70bn₩93.71bn₩103.95bn₩168.93bn₩174.19bn₩152.29bn₩116.41bn₩102.38bn₩89.13bn
Total liabilities₩299.16bn₩274.19bn₩263.36bn₩266.39bn₩295.51bn₩251.80bn₩181.51bn₩167.22bn₩109.37bn₩87.78bn
Debt₩15.69bn₩80.69bn₩104.75bn₩91.38bn₩120.25bn₩88.45bn₩60.29bn₩55.29bn₩9.88bn₩5.62bn
Shareholders' equity₩663.74bn₩603.48bn₩544.69bn₩501.94bn₩454.57bn₩411.37bn₩362.87bn₩313.02bn₩263.94bn₩237.32bn
Shares outstanding44m44m44m44m44m44m44m9m9m44m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩68.76bn₩76.09bn₩41.79bn₩40.91bn₩44.65bn₩59.11bn₩69.48bn₩33.21bn₩28.66bn₩39.41bn
Capital spending−₩46.00bn−₩30.80bn−₩39.35bn−₩51.23bn−₩51.01bn−₩39.61bn−₩25.13bn−₩75.46bn−₩11.67bn−₩9.62bn
Free cash flow₩22.76bn₩45.29bn₩2.44bn−₩10.32bn−₩6.35bn₩19.50bn₩44.35bn−₩42.25bn₩16.99bn₩29.79bn
Dividends paid−₩9.24bn−₩8.31bn−₩8.05bn−₩8.05bn−₩8.05bn−₩7.15bn−₩4.65bn−₩4.57bn−₩3.52bn−₩2.64bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩258.90bn₩251.02bn₩242.88bn₩226.81bn₩233.46bn₩223.74bn₩210.93bn₩200.88bn
Gross profit₩143.98bn₩140.81bn₩132.87bn₩124.42bn₩124.40bn₩119.92bn₩113.77bn₩111.44bn
Operating income₩26.09bn₩27.34bn₩24.30bn₩24.80bn₩28.78bn₩24.44bn₩17.65bn₩22.53bn
Net income₩17.55bn₩24.95bn₩13.85bn₩19.95bn₩15.77bn₩16.45bn₩8.63bn₩19.30bn
Diluted earnings per share389.03553.06307.04449.45355.15370.60196.28438.88
Cash from operations₩32.26bn₩22.58bn₩23.53bn₩11.38bn₩23.02bn₩10.83bn₩76.09bn₩45.53bn
Capital spending−₩20.17bn−₩13.54bn−₩14.42bn−₩10.89bn−₩14.66bn−₩6.03bn−₩30.80bn−₩24.67bn
Free cash flow₩12.08bn₩9.04bn₩9.12bn₩490.0m₩8.36bn₩4.80bn₩45.29bn₩20.86bn
Total assets₩1.12trn₩1.09trn₩1.06trn₩1.04trn₩998.44bn₩983.30bn₩953.16bn₩921.25bn
Cash and short-term investments—————₩114.14bn₩88.70bn₩87.16bn
Debt₩15.49bn₩15.59bn₩15.69bn₩15.79bn₩22.21bn₩73.11bn₩75.37bn₩71.77bn
Shareholders' equity₩696.63bn₩679.27bn₩663.74bn₩644.97bn₩625.77bn₩609.86bn₩603.48bn₩577.62bn

Financial ratios

Data as of 29 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017
Gross margin54.1%55.1%56.2%57.4%58.9%60.3%——
Operating margin10.4%9.9%9.1%11.0%10.6%15.2%——
Net margin7.1%7.5%6.5%8.0%8.5%10.0%——
Return on equity9.9%10.1%8.7%10.5%11.1%13.6%——
Return on assets6.2%6.4%5.6%6.9%6.7%8.4%——
Free cash flow yield——————56.0%21.3%
Revenue growth14.1%11.1%10.5%11.4%6.3%15.9%——
Earnings growth7.8%29.8%-10.8%5.1%-10.0%-0.7%——
Current ratio2.11x2.02x1.81x1.94x1.91x2.75x——
Debt to equity0.02x0.12x0.12x0.12x0.20x0.15x——
Equity ratio62.4%63.3%64.9%65.3%60.6%62.0%——
Interest coverage46.48x17.88x11.40x16.82x21.93x47.17x——
R&D as a share of sales3.5%3.7%3.5%3.5%4.2%3.4%——
Buybacks as a share of market value——————-2.7%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.9%10.6%13.6%
Operating income9.9%2.6%11.1%
Net income7.7%3.4%9.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin54.6%55.6%56.7%57.4%
Operating margin10.2%10.1%10.8%11.8%
Net margin7.3%7.3%7.8%8.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings11.511.915.113.819.023.013.92.22.812.4
Price to sales0.80.91.01.11.62.31.60.30.31.6

Dividends and splits

Per share, in the currency the company pays

Paid for 19 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year200.00380.00180.00180.00180.00160.00104.00104.00
  • 5-for-1 split · 10 Sept 2020
  • 13-for-10 split · 25 Jun 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.